The Trump administration soon plans to launch TrumpRx, a website it says will allow patients to buy prescription drugs directly from pharmaceutical companies at a discount. Over several months, the administration has made deals with more than a dozen pharmaceutical manufacturers to expand access to their drugs through the platform.
On Thursday, Sens. Dick Durbin (D-Ill.), Elizabeth Warren (D-Mass.), and Peter Welch (D-Vt.) sent a letter to the Office of Inspector General at the Department of Health and Human Services raising questions about TrumpRx — whose structure has yet to be described in detail — and the direct-to-consumer platforms that patients may be funneled toward in search of the lower costs touted by the website.
“Legitimate concerns about inappropriate prescribing, conflicts of interest, and inadequate care have been raised about the exact types of DTC platforms to which TrumpRx would route patients,” the senators wrote in the letter.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
